September 30, 2020
Enrolment: The meeting is designed for scientist and consultants
This meeting is designed as a unique space to share ideas and data on MRI contrast agent research and possible gadolinium toxicity after the administration of gadolinium-based contrast agents (GBCAs). We believe that joint international efforts will remain essential to optimize diagnostic efficacy and improve patient safety in MR imaging.
After the European Medicines Agency (EMA) recommended the suspension of the marketing authorization for high-risk GBCAs, the European landscape has changed significantly. Despite the recognition that linear GBCAs are depositing more gadolinium than macrocyclic GBCAs, no health effects have been associated with either class of agents.
This 5th GREC meeting will address some relevant issues related to the use of GBCAs in MRI, such as its effect in the environment, the potential clinical/histological consequences of their use in humans and animals, the development of a new-generation of high-relaxivity gadolinium chelates and of new non-GBCAs, and the implementation of strategies to reduce the use of GBCAs in different clinical situations.
We look forward to seeing you in Barcelona!
Institutional Scientific Patronage provided by ESMRMB.
- To present state of the research on:
- gadolinium deposition and related GBCA toxicity issues
- GBCA alternatives and solutions for Gadolinium-free MRI
- Sustainable GBCA use and GBCA in the environment
- To further develop and improve preclinical and clinical GBCA research
- To provide guidelines and recommendations on the use of GBCAs
08:30-09:15 – Business Meeting (reserved for GREC members)
09:20-09:30 – Welcome and practical meeting issues
Session 1 - ESMRMB-GREC Committee
09:30-09:40 – Introduction by ESMRMB-GREC Chairs (C.C. Quattrocchi, A. Nederveen)
09:40-09:50 – GREC educational activities for ESMRMB 2020
09:50-10:20 – Selection of abstracts from ESMRMB/ISMRM 2020
10:20 – 10:50 – Gadolinium Deposition Disease. Does it Exist?
10:50-11:00 – Discussion
Session 2 - 2020 Update on Gadolinium Research
11:30-11:45 – What is New in Gadolinium Chemistry & Speciation
11:45-12:00 – What is New in Gadolinium Deposition & Toxicity in the Brain & Body
12:00-12:15 – What is New in Stability of Gadolinium-based Constrast Agents
12:15-12:30 – What is New in Imaging of the Brain Glymphatic Clearance Pathway
12:30-12:40 – Questions and Discussion
12:40 – 13:30
Session 3 - Gadolinium in the Environment
13:30-13:45 – GBCAs Use and Trends in Europe
13:45-14:00 – GBCAs Use and Trends in Non-European Countries
14:00-14:15 – GBCA in Waste / River Water
14:15-14:30 – GBCA in Drinking Water
14:30-14:45 – Removal of Gadolinium from the Environment
14:45-14:50 – Questions & Discussions
Session 4 - New Contrast Agents and Gadolinium Alternatives
15:10-15:20 – High-relaxivity GBCAs
15:20-15:30 – High-relaxivity GBCAs
15.30-15.45 – Non-Gadolinium Based Contrast Agents
15:45-16:00 – Non-Gadolinium Based Contrast Agents: Clinical Applications
16:00-16:10 Questions & Discussion
Session 5 - Gadolinium Dose Reduction / Gadolinium-free MRI strategies
16:10-16:20 – GBCAs overuse
16:20-16:30 – CNS MRI
16:30-16:40 – Cardiovascular MRI
16.40-16:50 – MSK MRI
16:50-17:00 – Abdominal MRI
17:00-17:10 – Questions & Discussion
Summary & Conclusions
Session 6 - Creation of Working Groups
17:20-17:40 Indications of GBCA in clinical practice: Guidelines/Recommendation Papers
17:40-17:50 European Survey on the Use of GBCAs (in collaboration with ESR)
17:50-18:00 – Adjourn
Please contact us at email@example.com for any questions related to the ESMRMB-GREC 2020 meeting registration or by phone at (+43) 1 533 4064 915.